Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Critical appraisal of the role of pegloticase in the management of gout.

Ea HK, Richette P.

Open Access Rheumatol. 2012 Jun 26;4:63-70. eCollection 2012. Review.

2.

Drug therapy management in patients with renal impairment: how to use creatinine-based formulas in clinical practice.

Eppenga WL, Kramers C, Derijks HJ, Wensing M, Wetzels JF, De Smet PA.

Eur J Clin Pharmacol. 2016 Dec;72(12):1433-1439. Epub 2016 Aug 27.

3.

Poorly controlled gout: who is doing poorly?

Chia FL.

Singapore Med J. 2016 Aug;57(8):412-4. doi: 10.11622/smedj.2016129.

4.

Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications.

Sattui SE, Gaffo AL.

Ther Adv Musculoskelet Dis. 2016 Aug;8(4):145-59. doi: 10.1177/1759720X16646703. Epub 2016 May 2. Review.

5.

Predicting allopurinol response in patients with gout.

Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK.

Br J Clin Pharmacol. 2016 Feb;81(2):277-89. doi: 10.1111/bcp.12799. Epub 2015 Dec 29.

6.

Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists.

Vargas-Santos AB, Castelar-Pinheiro Gda R, Coutinho ES, Schumacher HR Jr, Singh JA, Schlesinger N.

PLoS One. 2015 Aug 14;10(8):e0135805. doi: 10.1371/journal.pone.0135805. eCollection 2015.

7.

Remembering the forgotten non-communicable diseases.

Lopez AD, Williams TN, Levin A, Tonelli M, Singh JA, Burney PG, Rehm J, Volkow ND, Koob G, Ferri CP.

BMC Med. 2014 Oct 22;12:200. doi: 10.1186/s12916-014-0200-8.

8.

Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.

Rashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, Mikuls TR.

J Rheumatol. 2015 Mar;42(3):504-12. doi: 10.3899/jrheum.140588. Epub 2014 Dec 15.

9.

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.

Tsuruta Y, Mochizuki T, Moriyama T, Itabashi M, Takei T, Tsuchiya K, Nitta K.

Clin Rheumatol. 2014 Nov;33(11):1643-8. doi: 10.1007/s10067-014-2745-5. Epub 2014 Jul 22.

10.

Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout.

Stamp LK, Merriman TR, Barclay ML, Singh JA, Roberts RL, Wright DF, Dalbeth N.

Semin Arthritis Rheum. 2014 Oct;44(2):170-4. doi: 10.1016/j.semarthrit.2014.05.007. Epub 2014 May 9. Review.

11.

Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study.

Goldfien RD, Ng MS, Yip G, Hwe A, Jacobson A, Pressman A, Avins AL.

BMJ Open. 2014 Jan 10;4(1):e003627. doi: 10.1136/bmjopen-2013-003627.

12.

Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.

Sivera F, Andrés M, Carmona L, Kydd AS, Moi J, Seth R, Sriranganathan M, van Durme C, van Echteld I, Vinik O, Wechalekar MD, Aletaha D, Bombardier C, Buchbinder R, Edwards CJ, Landewé RB, Bijlsma JW, Branco JC, Burgos-Vargas R, Catrina AI, Elewaut D, Ferrari AJ, Kiely P, Leeb BF, Montecucco C, Müller-Ladner U, Ostergaard M, Zochling J, Falzon L, van der Heijde DM.

Ann Rheum Dis. 2014 Feb;73(2):328-35. doi: 10.1136/annrheumdis-2013-203325. Epub 2013 Jul 18.

13.

Diabetes and gout: efficacy and safety of febuxostat and allopurinol.

Becker MA, MacDonald PA, Hunt BJ, Jackson RL.

Diabetes Obes Metab. 2013 Nov;15(11):1049-55. doi: 10.1111/dom.12135. Epub 2013 Jun 12.

14.

Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.

Graham GG, Kannangara DR, Stocker SL, Portek I, Pile KD, Indraratna PL, Datta I, Williams KM, Day RO.

Br J Clin Pharmacol. 2013 Dec;76(6):932-8. doi: 10.1111/bcp.12126.

15.

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R; American College of Rheumatology..

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46. doi: 10.1002/acr.21772. No abstract available.

16.

Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.

Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ.

BMC Musculoskelet Disord. 2012 Sep 16;13:174. doi: 10.1186/1471-2474-13-174.

17.

Untargeted plasma metabolite profiling reveals the broad systemic consequences of xanthine oxidoreductase inactivation in mice.

Chen Q, Park HC, Goligorsky MS, Chander P, Fischer SM, Gross SS.

PLoS One. 2012;7(6):e37149. doi: 10.1371/journal.pone.0037149. Epub 2012 Jun 18.

18.

Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.

Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, Cronstein BN, Sedlis SP, Pillinger MH.

J Rheumatol. 2012 Jul;39(7):1458-64. doi: 10.3899/jrheum.111533. Epub 2012 Jun 1.

19.

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

Jackson RL, Hunt B, MacDonald PA.

BMC Geriatr. 2012 Mar 21;12:11. doi: 10.1186/1471-2318-12-11.

20.

The pharmacokinetics of oxypurinol in people with gout.

Stocker SL, McLachlan AJ, Savic RM, Kirkpatrick CM, Graham GG, Williams KM, Day RO.

Br J Clin Pharmacol. 2012 Sep;74(3):477-89. doi: 10.1111/j.1365-2125.2012.04207.x.

Supplemental Content

Support Center